Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALKBH1 | Q13686 | 4/20 | 0.56 |
| ▸ | EGLN1 | Q9GZT9 | 11/20 | 0.55 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.53 |
| ▸ | ALKBH2 | Q6NS38 | 2/20 | 0.51 |
| ▸ | HPGDS | O60760 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30529091 | 1.00 | ALKBH1 (0.56) | ALKBH1EGLN1ACKR3ALKBH2HPGDS | |
| SCHEMBL182148 | 0.88 | BCL2L1 (0.49) | ALKBH1EGLN1ACKR3NPC1RAB9A | |
| SCHEMBL20263307 | 0.87 | ACKR3 (0.52) | ALKBH1EGLN1ACKR3NPC1RAB9A | |
| SCHEMBL25342571 | 0.85 | EGLN1 (0.53) | ALKBH1EGLN1ALKBH2HPGDSNPC1 | |
| SCHEMBL30037250 | 0.84 | ACKR3 (0.50) | ALKBH1EGLN1ACKR3NPC1RAB9A | |
| SCHEMBL2561296 | 0.84 | HPGDS (0.51) | EGLN1ALKBH2HPGDS | |
| SCHEMBL20162802 | 0.84 | ACKR3 (0.50) | ALKBH1EGLN1ACKR3NPC1RAB9A | |
| SCHEMBL14150459 | 0.82 | ALKBH1 (0.49) | ALKBH1EGLN1ALKBH2HPGDS | |
| SCHEMBL182131 | 0.82 | MEN1 (0.54) | ALKBH1EGLN1ACKR3NPC1RAB9A | |
| SCHEMBL22209199 | 0.81 | ALKBH2 (0.63) | ALKBH1EGLN1ALKBH2HPGDS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250170117-A1 | MODULATORS OF ACKR3 AND USES THEREOF | INTERAX BIOTECH AG (CH) | 2025-05-29 | — | — | US | disclosed |
| CN-119661538-A | Pyrazolo [3,4-d ] pyrimidine-4-ketone derivative and application thereof | 中国科学院精密测量科学与技术创新研究院 | 2025-03-21 | — | — | CN | disclosed |
| WO-2023166190-A1 | MODULATORS OF ACKR3 AND USES THEREOF | INTERAX BIOTECH AG (CH) | 2023-09-07 | — | — | WO | disclosed |
| EP-3490986-A1 | PIPERIDINE CXCR7 RECEPTOR MODULATORS | Idorsia Pharmaceuticals Ltd (CH) | 2019-06-05 | — | — | EP | disclosed |
| WO-2018019929-A1 | PIPERIDINE CXCR7 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-02-01 | — | — | WO | disclosed |
| US-20080200519-A1 | TETRAHYDRONAPHTHALENYLAMIDES, A PROCESS FOR THEIR PRODUCTION AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | BAYER SCHERING PHARMA AG (DE) | 2008-08-21 | — | — | US | disclosed |
| EP-1958934-A1 | Tetrahydronaphthalenylamides, a process for their production and their use as anti-inflammatory agents | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-08-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250170117-A1 | MODULATORS OF ACKR3 AND USES THEREOF | ACKR3, PROKR2, PROKR1 | ALKBH1 3142/4885EGLN1 951/4885ACKR3 1/4885 |
| US-20080200519-A1 | TETRAHYDRONAPHTHALENYLAMIDES, A PROCESS FOR THEIR PRODUCTION AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | PTGES, PTGS1, PTGS2 | ALKBH1 803/4885EGLN1 930/4885ACKR3 2282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.